| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2023 | SUPN Supernus Pharmaceuticals, Inc. | Khattar Jack A.64 | President, CEO | Sell | 13,732 | $42.05 | $577,492.26 | -0.8% | -12.4% | -33.5% | |
| Feb 2, 2023 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $254.63 | $1,527,793.64 | -5.1% | -15.8% | -17.8% | |
| Feb 2, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $258.28 | $4,132,513.40 | -33.5% | -15.8% | -17.8% | |
| Feb 1, 2023 | BCRX Biocryst Pharmaceuticals Inc | Stonehouse Jon P80 | President &CEO | Sell | 100,000 | $10.38 | $1,038,000.00 | -9.0% | -29.9% | -49.8% | |
| Feb 1, 2023 | UTHR United Therapeutics Corp | Sullivan Louis W62 | Director | Sell | 700 | $261.33 | $182,931.00 | -5.4% | -12.0% | -16.9% | |
| Feb 1, 2023 | SUPN Supernus Pharmaceuticals, Inc. | Khattar Jack A.64 | President, CEO | Sell | 300 | $42.01 | $12,602.01 | - | -10.3% | -33.0% | |
| Feb 1, 2023 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $30.35 | $15,175.65 | -0.6% | +20.7% | +74.7% | |
| Jan 31, 2023 | SUPN Supernus Pharmaceuticals, Inc. | Khattar Jack A.64 | President, CEO | Sell | 976 | $42.01 | $41,002.35 | -0.1% | -9.9% | -32.5% | |
| Jan 31, 2023 | NBIX Neurocrine Biosciences Inc | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 1,104 | $109.92 | $121,348.59 | -22.0% | -6.2% | +26.0% | |
| Jan 31, 2023 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 1,207 | $109.95 | $132,710.25 | -6.7% | -6.2% | +26.0% | |
| Jan 31, 2023 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 1,283 | $109.98 | $141,107.80 | -5.7% | -6.2% | +26.0% | |
| Jan 31, 2023 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 2,707 | $110.08 | $297,997.12 | -0.6% | -6.2% | +26.0% | |
| Jan 31, 2023 | NBIX Neurocrine Biosciences Inc | Onyia Jude54 | Chief Scientific Officer | Sell | 126 | $108.48 | $13,668.48 | -4.8% | -6.2% | +26.0% | |
| Jan 31, 2023 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 1,250 | $109.97 | $137,464.00 | -4.0% | -6.2% | +26.0% | |
| Jan 31, 2023 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 1,457 | $109.99 | $160,253.54 | -5.3% | -6.2% | +26.0% | |
| Jan 31, 2023 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 1,541 | $109.98 | $169,486.42 | -1.3% | -6.2% | +26.0% | |
| Jan 31, 2023 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 50,000 | $8.14 | $407,000.00 | -17.4% | +45.2% | +3.6% | |
| Jan 31, 2023 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 916 | $108.48 | $99,367.68 | -5.4% | -6.2% | +26.0% | |
| Jan 31, 2023 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Integration Officer | Sell | 1,666 | $110.02 | $183,290.49 | -5.5% | -6.2% | +26.0% | |
| Jan 31, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $260.76 | $4,172,125.69 | -42.6% | -11.8% | -18.4% | |
| Jan 27, 2023 | TXMD Therapeuticsmd, Inc. | Donegan Michael C85 | Prin. Fin. And Acctg. Officer | Sell | 1,697 | $5.08 | $8,620.59 | -6.7% | -32.0% | -57.5% | |
| Jan 27, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $262.12 | $4,193,841.14 | -51.4% | -12.3% | -16.0% | |
| Jan 25, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $261.88 | $4,190,115.90 | -29.3% | -14.9% | -17.5% | |
| Jan 24, 2023 | TXMD Therapeuticsmd, Inc. | Donegan Michael C85 | Prin. Fin. And Acctg. Officer | Sell | 1,309 | $5.34 | $6,987.64 | -7.9% | -29.4% | -56.3% | |
| Jan 23, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $259.79 | $4,156,674.03 | -39.8% | -11.8% | -15.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.